Spyre Therapeutics Launches Public Offering to Fund SPY072 Late-Stage Push
SYRE has more than doubled off its 52-week low of $15.86.
Summary
Spyre Therapeutics priced its public offering at $85 per share for 4,117,648 shares, raising $350.0 million, with net proceeds earmarked for advancing its pipeline and SPY072 late-stage development. This follows positive Phase 2 data for SPY003 in ulcerative colitis and a strategic shift for SPY072 in rheumatoid arthritis. The capital raise is dilutive to existing shareholders and comes after insider sales under 10b5-1 plans.
Updated with a Reuters report · What changed
Updates
· Reuters — Spyre priced the offering at $85 per share for 4,117,648 shares, raising $350.0 million.
At the time of this announcement, SYRE was trading at $89.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2B. The 52-week trading range was $15.86 to $110.18. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.